Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"expected initiation of its pivotal, registration trial in complex cardiac surgery by the end of this year." From the PR this morning regarding Deloitte's 2017 Technology Fast 500 "As CytoSorbents drives to operating profitability, expected in 2018, it is also pursuing U.S. approval with the expected initiation of its pivotal, registration trial in complex cardiac surgery by the end of this year."
From the companies latest presentation at the Bio Investor Forum, slide 16. "Over the past 3 years, the compound growth rate of return (CAGR) was 81%.
https://seekingalpha.com/article/4114820-cytosorbents-ctso-presents-2017-bio-investor-forum-slideshow?app=1&auth_param=7ihl:1cui0nr:741fd5a5937226c385957a2115d148df&uprof=11
Also, from the last earnings, Q2 2017 earnings were 17% over Q1 2017 earnings. I doubt that you can find many companies that are growing at this pace and have the potential to keep growing at this pace. That is what makes CTSO so phenomenal.
I disagree that it has become a trader's play. Yes, you can trade and generally guess correctly, but what about the traders that sold for $6.00 the last trading session and woke up to a $6.30 open, then moved higher? This company has moved from the $4.00 to $6.45 range very quickly and as we near breakeven it will fly much higher. Remember about 60% of sales over breakeven will fall to the bottom line, that is huge. i would not want to be out of CTSO as that happens. I was not irrationally exuberant about the recent share price increases, I believe that you were irrationally exuberant about your chances of purchasing shares at $5.45.
no, I was referring to paulsby post of October 24th where he stated that he would be a buyer at $5.45. It never dropped to his price.
buyer at 5.45 pps, pearsby I don't think you are going to be getting any shares for 5.45.
This company has so much potential, saved lives of H1N1 patients in India, a Multiple Sclerosis patient treated in Switzerland. Saving lives in so many different indications. Whenever I think of investing additional money that I accumulate, I try to think of different companies that would potentially bring in a high return, but nowhere can I find another company that compares with CTSO's potential. It is small, undervalued and ready to explode.
So, to condense your rambling, you would have a large dilution? I prefer Dr. Chan's strategy. That is to have independent researchers/universities perform the studies, which cost the company nothing.They have supplied evidence that the beads work, that they work for morbidity/mortality. As for the larger trials, just because we have not had a partner yet for the large study, does not mean that there isn't one in the works. Sales are increasing rapidly, 80% year over year so the word is getting out. There should not be any need for dilution for salaries, etc. as Dr. Chan has stated that the company will break even next year.
There was no money spent, only cartridges were supplied. So, the company gets more evidence that the beads are working well at no cost. I have to ask you again, how should the company pay for the large study, that would cost $20-40 million?I have yet to get a straight answer. You mentioned that they could eliminate the smaller studies, but they cost the company nothing but the cartridges. My guess is that eventually a partner will pay or share the cost of a larger study.
Why the big jump in volume and to 6.25? can't see any news.
With earnings coming up in two weeks, I believe that you made a very wise investment.
• Data from the business valuation community, Mergerstat® in particular, has generally indicated a control premium percentage in takeover situations from the low 20’s to high 30’s over the past decade. Much of the premium in these situations is driven either by a formal process or by the threat of a process leading to a preemptive bid from the acquirer.
• For the 100+ public companies acquired in 2013 with pre-announcement market caps over $50 million, the average premium to the share price a month before the announcement was 37%. [1]. Looking back over the past 10 years, the premium has also averaged 37%.
• For targets under $100 million market cap, premiums have tended to be higher. Over the past 10 years, transactions in this range averaged a 50% one-month premium. Targets this size commanding the highest premiums tend to be biotech and software/IT businesses.
http://merger.com/ma-question-dont/
Why would anyone want a buyout for maybe as high as $9/share when we are just hitting our inflection point? Could easily be worth $20/share within a year or so.
Why would anyone want a buyout? What would it bring today, maybe $9/share. The company could be worth $20 in a year, $30 in two years.
The cases are "cherry picked" to show doctors around the world how many indications that Cytosorb can be used for to save thousands of lives. It started with sepsis, but now is used for organ transplants, heart surgery, influenza, burn injuries, trauma, cytokine release syndrome, lung injury, pancreatitis, liver failure, etc. The "cherry picked cases" of the future will show it's use in CAR T therapy, MERS, etc. Saving lives, one at a time paulsby.
Pearsby, you post this on a monthly basis. Everyone would like a Large Scale Multi Centered Placebo Controlled study. However, this is the part that you will not answer, how does the company pay for it? They are preparing for REFRESH2 already to get their foot in the door. They had to dilute to pay for that. I am sure that they have search for partners for a sepis study. Surely you are not asking for more dilution?
While there is not doubt that the Beads will sell more with Valid and Reliable large scale data, and it will come, CTSO is about to burst past the 4.50 to 6.75 range. It will do this because sales are already increasing 80% per year without the data. The company will be profitable in 2018 and then be bursting to the $20 - $30 range because of it's 68% margins, which will increase even more as sales continue to increase.
so pearsby, are you saying that the company should ignore the new and potential revenue streams that keep appearing like CAR T, potassium reduction, organ transplant? The company is not spending much of it's own resources on any of those, other companies, interests are doing the heavy lifting for us. The company supplies filters and coordination. Those streams could turn into revenue rivers.
Dr. June being on the board does not automatically produce compelling data, but he knows what Cytosorb can do and he is THE pioneer of CAR T treatment. He joined Cytosorbents for one reason and that is to develop the use of Cytosorb along with CAR T treatments. Cytosorb is a cytokine controller, is approved for that use in the EU and that is what they need.
the poster did say that he is German, his English may not translate as well as we would like.
Dr. Chan stated that the expansion for doubling production is already underway at a greatly reduced cost.
That is great, also Dr. Ian Stewart that performed that worked on K+ontrol, is the same doctor that was assigned to the Rhabdomyolyis trial Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis at Fort Sam Houston in San Antonio earlier.
How can you state that there will probably not be good data on CAR T, they have the pioneer of CAR T, Dr. June on their staff. The reason is very clear, the therapy needs a treatment for the cytokine cascade that ensues. What cost has been shifted to the shareholders? We company supplies filters that cost $50 each. Interested, convinced Universities and hospitals bear the cost of the trials.
You preach the large scale well designed trial over and over.I am here to partially refute that. Yes, in an ideal world that is what the company would do. However, it has limited resources and Dr. Chan has done a great job of limiting dilution, there are only 30 million shares, which is almost unheard of. The company is marshaling it's resources for the REFRESH 2 trial which will open the door to sales in the US. Meanwhile, China can approve the use of Cytosorb, at no cost to the company, to treat a potential epidemic. You criticize the shotgun approach but multiple indications are being added at absolutely no cost to the company and others like CAR T cell will follow.
There is a new pneumonia appearing in China that is incredibly drug resistant with a high mortality rate. It has resisted 26 antibiotics and results in a proinflammatory cytokine cascade. Perhaps our filter could treat these people?
http://www.npr.org/sections/goatsandsoda/2017/09/02/547892623/triple-threat-new-pneumonia-is-drug-resistant-deadly-and-contagious
Thanks for the two interesting articles techxen. It appears that we are partnered very well for the future. I am excited that we have so many "shots on goal" with heart surgery, sepsis, AKI, cancer, biowarfare, blood transfusions, universal donor, etc. Sales are ramping up, partnerships are beginning to pay off and the company will be profitable within a year with 68+% margins.
The product works, and for many other indications that cancer immunology.
One third of sales are not coming from one hospital. The German hospital had $1 million in Cytosorb annual sales. The Q2 2017 sales figures were for $3 million for the quarter, not the year. Projected 2017 sales are $14 million, so that would be approximately 7% of their sales from one hospital, not one third.
This is an interesting case, it illustrates how the use of Cytosorb is spreading. It helped to save the life of a 5 year old Down Syndrome girl. BACKGROUND: Toxic shock syndrome is a potentially fatal toxin-mediated disease. The role of toxins in this clinical entity made us hypothesize that extracorporeal blood purification with CytoSorb® could play a beneficial role in the clinical management of toxic shock syndrome. This case report describes the successful treatment of toxic shock syndrome using a combination of renal replacement therapy and hemadsorption in a pediatric patient.
CASE PRESENTATION: A 5-year-old girl with Down's syndrome presented with an inflamed area surrounding an insect bite, signs of systemic inflammation, and multiple organ failure. As previous attempts of immune modulation therapy were unsuccessful, renal replacement therapy was supplemented by the cytokine absorber CytoSorb. Treatment using this combination was associated with a rapid and significant stabilization in the hemodynamic situation and a decrease in inflammatory mediators within hours after the initiation of therapy. The application of CytoSorb therapy was simple and safe.
CONCLUSION: The use of extracorporeal blood purification with CytoSorb proved potentially beneficial by removing toxins and inflammatory mediators in this case and could therefore play a role in the clinical management of toxic shock syndrome. Whether CytoSorb has the potential to even positively influence mortality in patients with toxic shock syndrome still needs to be confirmed.
I have googled the author of last Friday's Seeking Alpha article regarding CTSO, C.C. Abbott and cannot find anything at all about her. This article was published the day before earnings and caused the share price to drop drastically. It is like she doesn't exist.
We have partnered with NX STage. In August 2012, we were awarded a $3.8 million, five-year contract by DARPA for our DLT, program to treat sepsis. DARPA has been instrumental in funding many of the major technological and medical advances since its inception in 1958, including development of the Internet, development of GPS, and robotic surgery. The DLT program in sepsis seeks to develop a therapeutic blood purification device that is capable of identifying the cause of sepsis (e.g., cytokines, toxins, pathogens, activated cells) and remove these substances in an intelligent, automated, and efficient manner. Our contract is for advanced technology development of our hemocompatible porous polymer technologies to remove cytokines and a number of pathogen and biowarfare toxins from blood. We are in Year 5 of the program and are currently working with the systems integrator, Battelle Laboratories, and its subcontractor NxStage Medical, who are responsible for integrating the technology developed by us and others into a final medical device design prototype, and evaluating this device in septic animals and eventually in human clinical trials in sepsis. Our work is supported by DARPA and SSC Pacific under Contract No. N66001-12-C-4199. In June 2016, this contract was amended to change the maximum funding to approximately $3,825,000. As of December 31, 2016, we have received approximately $3,739,000 in funding under this contract and have approximately $86,000 remaining under this contract.
pearsby, all of your numbers are off. Any company would kill for a 17% quarterly increase. Dr. Chan has stated that we will be at $20 million in sales and at breakeven in 2018. We will not be sub $10 million for 5 or more additional years as you state. The Cytosorb filters are working fine, the XL version will increase performance and enhance the patents.
Dr. Chan seems to have focused on cardiac surgery, that is the upcoming large scale FDA trial. Meanwhile, this new study seems to indicate promise in yet another area. Why not follow up on another indication? It will mean yet more sales as Cytosorb is already approved for cytokine reduction. All Cytosorb had to do was supply filters to the researchers for this study.
you mean no proven effective therapy for cancer, not sepsis correct?
there is not one iota of evidence that NVS is not interested in CTSO
Bret Jensen
Founder, Biotech Forum
Disclosure: I am/we are long AGN, CTSO.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
CTSO does not pay Bret Jensen for his articles. You can pay him to receive his articles before others but that is up to the individual investor. The part of his article that I liked the most was how he compared CTSO with a "busted IPO" ZLTQ. Mr. Jensen states their similarities and how ZLTQ went on to become an " 11 bagger" for him. Cytosorbents has that same possibility.
I disagree pearsby, the device is approved for cytokine reduction, Novartis f has it's headquarters in Switzerland, CTSO has it's wholly owned subsidiary CytoSorbents Switzerland is there, THE pioneer of CART T treatment Jr. June was hired recently, it all adds up to you probably need to cover your shorts soon.
The company is not targeting all cancer's, they are after the CART T treatments, reducing cytokine storm, which is exactly what Cytosorb does. There is NO daily long term treatment in what they hope to treat. Hence, it is convenient and practical. Yes, there could be long term trials before the FDA would approve it's use, but it could be fast tracked. Also, it can be used tomorrow in the 43 countries that are already approved to treat this after effect of CART T treatments. Remember the genius of the company is that it is approved as a cytokine reducer.
They could actually be break even in 6 months instead of a year. Also, from Bridge Banks comments, it appears that it would not be a problem to borrow more money. I Feel sure that there will be an announcement to that effect before long, a letter of credit. "We have been working with CytoSorbents for over a year now and have been pleased with their performance and progress over that time. We believe they possess a truly innovative technology in the life sciences space which could transform critical care medicine and cardiac surgery and save lives throughout the world," said Mr. Justin McDonie, Senior Vice President and Managing Director for Bridge Bank. "We are pleased to provide this additional capital to support CytoSorbents' growth at this important juncture in their evolution."
This PR demonstrates the current cash flow situation. The company has forecast breakeven in 2018. Part of the loan will fund the large scale REFRESH 2 FDA TRIAL. "With our existing cash on hand, this non-dilutive financing further strengthens our balance sheet at an attractive cost of capital and provides sufficient working capital for the foreseeable future, allowing us to continue to pursue our aggressive growth strategy and clinical trial objectives as we increase product sales worldwide and move closer to operating cash flow breakeven," stated Ms. Kathleen P. Bloch, CPA, MBA, Chief Financial Officer of CytoSorbents Corporation.